Impact of Two Common Xeroderma Pigmentosum Group D (XPD) Gene Polymorphisms on Risk of Prostate Cancer

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Mi, Yuanyuan ^a   Zhang, Lifeng ^b   Feng, Ninghan ^c   Wu, Sheng ^a   You, Xiaoming ^a   Shao, Hongbao ^a   Dai, Feng ^a   Peng, Tao ^a   Qin, Feng ^a   Zou, Jiangang ^b   Zhu, Lijie ^a  

^a NANTONG UNIVERSITY   (China)

^b THE AFFILIATED CHANGZHOU NO 2 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; ASPARTIC ACID; GLUTAMINE; LYSINE; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

AFRICAN; ARTICLE; ASIAN; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; ETHNIC DIFFERENCE; ETHNIC GROUP; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; GLEASON SCORE; HUMAN; MOLECULAR PATHOLOGY; PROSTATE CANCER; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; XERODERMA PIGMENTOSUM GROUP D GENE;

AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84866674102     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044756     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Dunn MW, Kazer MW, (2011) Prostate cancer overview. Semin Oncol Nurs 27: 241-250.
3. Powell IJ, (2011) The precise role of ethnicity and family history on aggressive prostate cancer: a review analysis. Arch Esp Urol 64: 711-719.
4. Berwick M, Vineis P, (2000) Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 92: 874-897.
5. Wood RD, Mitchell M, Sgouros J, Lindahl T, (2001) Human DNA repair genes. Science 291: 1284-1289.
6. Thompson LH, West MG, (2000) XRCC1 keeps DNA from getting stranded. Mutat Res 459: 1-18.
7. Sancar A, Tang MS, (1993) Nucleotide excision repair. Photochem Photobiol 1993 57: 905-921.
8. Inoue R, Abe M, Nakabeppu Y, Sekiguchi M, Mori T, et al. (2000) Characterization of human polymorphic DNA repair methyltransferase. Pharmacogenetics 10: 59-66.
9. Kanaar R, Hoeijmakers JH, van Gent DC, (1998) lecular mechanisms of DNA double strand break repair. Trends Cell Biol 8: 483-489.
10. Hung RJ, Hall J, Brennan P, Boffetta P, (2005) Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol 162: 925-942.
11. Weber CA, Salazar EP, Stewart SA, Thompson LH, (1990) ERCC2: cDNA cloning and molecular characterization of a human nucleotide excision repair gene with high homology to yeast RAD3. EMBO J 9: 1437-1447.
12. Itin PH, Sarasin A, Pittelkow MR, (2001) Trichothiodystrophy: update on the sulfur-deficient brittle hair syndromes. J Am Acad Dermatol 44: 891-920.
13. Goode EL, Ulrich CM, Potter JD, (2002) Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11: 1513-1530.
14. Cleaver JE, (2000) Common pathways for ultraviolet skin carcinogenesis in the repair and replication defective groups of xeroderma pigmentosum. J Dermatol Sci 23: 1-11.
15. Evans E, Moggs JG, Hwang JR, Egly JM, Wood RD, (1997) Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J 16: 6559-6573.
16. Rybicki BA, Conti DV, Moreira A, Cicek M, Casey G, et al. (2004) DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 13: 23-29.
17. Shen MR, Jones IM, Mohrenweiser H, (1998) Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58: 604-608.
18. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, et al. (2000) XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21: 551-555.
19. Bau DT, Wu HC, Chiu CF, Lin CC, Hsu CM, et al. (2007) Association of XPD polymorphisms with prostate cancer in Taiwanese patients. Anticancer Res 27: 2893-2896.
20. Dhillon VS, Yeoh E, Fenech M, (2011) DNA repair gene polymorphisms and prostate cancer risk in South Australia-results of a pilot study. Urol Oncol 29: 641-646.
21. Ritchey JD, Huang WY, Chokkalingam AP, Gao YT, Deng J, et al. (2005) Genetic variants of DNA repair genes and prostate cancer: a population-based study. Cancer Epidemiol Biomarkers Prev 14: 1703-1709.
22. Gao R, Price DK, Dahut WL, Reed E, Figg WD, (2010) Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer. Cancer Biol Ther 10: 13-18.
23. Sobti RC, Berhane N, Melese S, Mahdi SA, Gupta L, et al. (2012) Impact of XPD gene polymorphism on risk of prostate cancer on north Indian population. Mol Cell Biochem 362: 263-268.
24. Lavender NA, Komolafe OO, Benford M, Brock G, Moore JH, et al. (2010) No association between variant DNA repair genes and prostate cancer risk among men of African descent. Prostate 70: 113-119.
25. Agalliu I, Kwon EM, Salinas CA, Koopmeiners JS, Ostrander EA, et al. (2010) Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study. Cancer Causes Control 21: 289-300.
26. Mandal RK, Gangwar R, Mandhani A, Mittal RD, (2010) DNA repair gene X-ray repair cross-complementing group 1 and xeroderma pigmentosum group D polymorphisms and risk of prostate cancer: a study from North India. DNA Cell Biol 29: 183-190.
27. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
28. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
29. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
30. Hayashino Y, Noguchi Y, Fukui T, (2005) Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol 15: 235-243.
31. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L, (2006) Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680.
32. Munafò MR, Flint J, (2004) Meta-analysis of genetic association studies. Trends Genet 20: 439-444.
33. Yuan H, Niu YM, Wang RX, Li HZ, Chen N, (2011) Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis. Genet Mol Res doi: 10.4238/2011.November.22.6.
34. Ding DP, Ma WL, He XF, Zhang Y, (2012) XPD Lys751Gln polymorphism and esophageal cancer susceptibility: a meta-analysis of case-control studies. Mol Biol Rep 39: 2533-2540.
35. Feng Z, Ni Y, Dong W, Shen H, Du J, (2012) Association of ERCC2/XPD polymorphisms and interaction with tobacco smoking in lung cancer susceptibility: a systemic review and meta-analysis. Mol Biol Rep 39: 57-69.
36. Pabalan N, Francisco-Pabalan O, Sung L, Jarjanazi H, Ozcelik H, (2010) Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer. Breast Cancer Res Treat 124: 531-541.
37. Camps C, Sirera R, Iranzo V, Tarón M, Rosell R, (2007) Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. Clin Lung Cancer 8: 369-375.
38. Baade PD, Youlden DR, Krnjacki LJ, (2009) International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 53: 171-184.
39. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A, (2010) Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 46: 3040-3052.